Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer

• DOI: 10.1126/scitranslmed.3007947
• Publication Date: 2014-02-19T14:15:49Z
• Authors: Sandra Misale; Sabrina Arena; Simona Lamba; Giulia Siravegna; Alice Lallo; Sebastijan Hobor; Mariangela Russo; Michela Buscarino; Luca Lazzari; Andrea Sartore-Bi...; Katia Bencardino; Alessio Amatu; Calogero Lauricella; Emanuele Valtorta; Salvatore Siena; Federica Di Nicol...; Alberto Bardelli
• Keywords: 0303 health sciences; Antineoplastic Agents; MAP Kinase Kinase Kinases; Antineoplastic Agents; Colorectal Neoplasms; Drug Resistance, Neoplasm; Gene Silencing; Humans; MAP Kinase Kinase Kinases; Receptor, Epidermal Growth Factor; Signal Transduction; Medicine (all); 3. Good health; ErbB Receptors; 03 medical and health sciences; CANCER; EGFR; MEK; Heterogeneous mechanisms; resistance; Colorectal cancer; Drug Resistance, Neoplasm; Humans; Gene Silencing; Colorectal Neoplasms; Signal Transduction

Colorectal cancers that become resistant to EGFR inhibitors through a variety of mechanisms can be effectively treated by inhibiting MEK in conjunction with EGFR.